Corbus Pharmaceuticals (CRBP) Rockets 80% YTD: A Good Buy Now?

If you are looking into stocks of companies that are going to announce their financial results today, then the Corbus Pharmaceuticals (NASDAQ: CRBP) stock could be one of the stocks to watch.

The company, which is involved in developing unique medicines meant for the endocannabinoid system, has already seen its stock soar by as cosmic as 83% this year already. It remains to be seen if investors flock to the stock this week after it announces its financial results for the full year 2020 and the fourth quarter.

Related:  CytoDyn (CYDY) Suddenly Turns Bearish As Huge Selling Pressure Occurs

According to Zacks Consensus Estimate, the company is expected to suffer a loss per share of $0.24. That represents a year-on-year rise of as much as 41.5% and it is a figure that is almost certainly going to be closely watched by analysts as well as investors. On the other hand, analysts expect Corbus to post revenues of $1.24 million in the quarter, which reflects a drop of as low as 51.8% from the year-ago period.

Uson Abdilazhanov

Editor and Computer Expert A hardcore tech enthusiast and computer expert Uson Abdilazhanov who holds a degree in communications started writing in his personal blogs since 2012. That time he was interested in the technical part of the computer. But now the software aspect plays an important role in his career. Currently, he runs a PC building and repairing shop which helps a lot of designers and gamers who always like to try new things.